Freenome (NASDAQ:FRNM) Upgraded to “Strong-Buy” at Jefferies Financial Group

Freenome (NASDAQ:FRNM) was upgraded by analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the company. BTIG Research began coverage on Freenome in a report on Monday. They issued a “buy” rating and a $17.00 price objective on the stock. Leerink Partners started coverage on shares of Freenome in a report on Friday. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, TD Cowen began coverage on shares of Freenome in a research report on Tuesday. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat, Freenome presently has a consensus rating of “Strong Buy” and a consensus price target of $17.33.

Freenome Stock Performance

Shares of NASDAQ FRNM opened at $13.00 on Monday. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26. The company has a market cap of $106.08 million, a PE ratio of -216.63 and a beta of 0.35.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.